Endo Pharmaceuticals purchased the US rights to the drug candidate Fortesta from ProStrakan Group PLC for an initial $10 million and a further $40 million by the end of 2010 if the drug is approved by regulators and achieves commercial milestones. Fortesta is a long-acting testosterone replacement injection intended for men whose bodies do not produce enough of the hormone. Endo could pay up to $160 million more if the product achieves sales targets. According to David Holveck, Endo"s president and CEO, the deal strengthens the company"s position in other therapeutic areas including urology and endocrinology
저작권자 © 메디칼업저버 무단전재 및 재배포 금지